Eli Lilly Obesity Drug - Search News

Eli Lilly, Wegovy and Zepbound

USA Today · 5h

Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.

MarketWatch on MSN · 5h

Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.

CNN on MSN · 5h

Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.

5h

Lilly's tirzepatide challenges semaglutide in obesity drug market

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...

Race is on for oral obesity drugs with multiple phase 3 trials vying for next-gen status in a $126B market

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results